Q2 Solutions brings more than 20 years of experience in bioanalytical services, developing robust methods to support all stages of drug discovery and development. We have developed and validated assays for a range of applications, including ADME screening/ADME testing, discovery and development metabolite identification, drug metabolism and pharmacokinetics, immunogenicity testing, biomarker analysis and characterization, and biosimilars testing. Methodologies include LC/MS bioanalysis, LC/MS/MS analysis, hybrid LC/MS assays, and immunoassay and MS-based biomarker assays. Prior to validation, each assay undergoes a formal pre-qualification process in which Q2 Solutions scientists review preliminary data and assess modifications necessary to support validation.
The link below provides a list of validated bioanalytical methods developed by Q2 Solutions to support clinical trial applications, including COVID-19 trials. In addition to listed assays, Q2 Solutions develops customized methods to meet specific challenges.
Specifica, a Q2 Solutions company, is applying its proven platform for antibody discovery to generate recombinant monoclonal antibody reagents. Our in vitro display approach eliminates the need for...
ImmunXperts, a Q2 Solutions company, provides functional insights into immune-mediated adverse events. We provide in silico and in vitro methods, using T-cell activation and proliferation as a...
If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...